AzTrials
AzTrials

Low-lying Unilateral Palpable Undescended TestisEXPRESSONCT02158780

Expertise-Based Randomized Controlled Trial of Scrotal Versus Inguinal Orchidopexy on Post-operative Pain

A study testing Scrotal Orchidopexy and Inguinal Orchidopexy in people with Low-lying Unilateral Palpable Undescended Testis, run by McMaster University at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Undescended Testis is the most common congenital abnormality of the genitalia in boys and it is commonly managed by surgical intervention. Evidence in the medical literature to support the superiority of either scrotal or inguinal (standard) orchidopexy is lacking. Read more about this study

Who is it for?
Ages 10 months to 7 years, men only
What is being tested?
Scrotal Orchidopexy and Inguinal Orchidopexy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
162 participants
Where
1 siteCanada
Study dates
Jan 2015to 22 Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 months to 7 years
  • Men only
  • No healthy volunteers
  • Child

Who may be able to join

  • Diagnosis with palpable undescended testis (or testes);
  • Child is between 10 mos - 7 years of age;
  • Child requires either scrotal or inguinal orchidopexy

Who cannot join

  • Laparoscopic surgery for intra-abdominal testis or peeping testis (carnalicular);
  • Child underwent previous orchidopexy surgery

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • McMaster Children Hospital

    Hamilton, Ontario, L8N 3Z5

Other trials in Canada

About this study

Official title: Expertise-Based Randomized Controlled Trial of Scrotal Versus Inguinal (Standard) Orchidopexy on Postoperative Pain: EXPRESSO Trial

Undescended Testis is the most common congenital abnormality of the genitalia in boys and it is commonly managed by surgical intervention. Evidence in the medical literature to support the superiority of either scrotal or inguinal (standard) orchidopexy is lacking. To determine which technique is superior, this study focuses on the degree of post-operative pain after surgery. Therefore, the objective of this randomized control trial is to determine if scrotal orchidopexy reduces postoperative pain in children diagnosed with undescended testis when compared to standard inguinal orchidopexy.

Read the detailed description

Undescended Testis is the most common congenital abnormality of the genitalia in boys and it is commonly managed by surgical intervention. Evidence in the medical literature to support the superiority of either scrotal or inguinal (standard) orchidopexy is lacking. To determine which technique is superior, this study focuses on the degree of post-operative pain after surgery. Therefore, the objective of this randomized control trial is to determine if scrotal orchidopexy reduces postoperative pain in children diagnosed with undescended testis when compared to standard inguinal orchidopexy. At the first pre-operative clinic visit participating paediatric urologist will diagnose patients with low-lying palpable UDT. Patients who meet eligibility criteria will be invited to participate in this trial. A computer generated randomization list will be created using random blocks of multiple sizes (4, 6 and 8), by the McMaster Paediatric Surgery Research Collaborative's web-based randomization system. Patients will be allocated to intervention (scrotal orchidopexy) or control (standard inguinal orchidopexy) groups by logging in to the secure central randomization website. Patients will be stratified and randomized by centre into a 1:1 parallel allocation ratio.Primary Outcome: Post-operative pain during recovery phase Sample size calculated using single primary outcome of analgesic use. However, pain will also be measured in alternative ways using pain scales as a secondary outcome. Analgesic use post-operatively (during hospital stay): Defined as the number of doses and total consumption of morphine (standardized dose of 0.2 mg/kg/dose orally or 0.02 to 0.1 mg/kg/dose IV) or oral acetaminophen (15mg/kg/dose) or Ibuprofen (10mg/kg/dose) administered by PACU and SDSU nurses following surgery. Analgesic use post-discharge: Defined as number of standardized doses and total consumption of acetaminophen (15 mg/kg/dose) and Ibuprofen (10 mg/kg/dose) administered by parent/guardian at home post-discharge.Secondary Outcomes: Duration of surgery, Pain Scores, Success rate, Complications. Duration of surgery (min): Defined as time beginning when anesthesia is ready until patient is moved to PACU. Recorded on patient discharge sheet by study nurse. Time to discharge: Defined as duration of time from entering PACU to readiness to discharge from PACU or same day-surgery unit (if applicable). Recording by study nurse on discharge sheet. Pain Scales post-operative:Mean of highest pain score in each patient: Self-reported pain scales are gold-standard for reporting pain; however, since this study sample comprises of pre-verbal children, an observer pain tool will be used. Specifically, pain scores will be measured through a reliable and validated observer-rated Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) and Face, Legs, Activity, Cry, Consolability (FLACC) Behavioural Scale30 by two trained, blinded, and independent study personnel. Both study personnel will measure pain at admission and discharge during the recovery phase. Recovery phase is defined as post-operative period in the post-anesthesia care unit (PACU) and same day surgery unit (SDSU). Patients usually recover for an average of two hours before being discharged. Highest pain score will be determined by blinded analysts. At monthly intervals, inter-rater reliability between study personnel will be assessed and re-trained to ensure high consistency in score ratings.

Mean overall pain sore: Average pain score (standard deviation) throughout recovery phase. Pain scales post-discharge: Information measured at home by parent/guardian. Collected by study personnel at 24 hour follow-up telephone call. Mean of the highest pain score in each patient: Assessed through validated and reliable Parents Postoperative Pain Measure (PPPM)and Toddler-Preschooler Postoperative Pain Scale (TPPPS) by trained and parent/guardian 24 hrs post-discharge. Complication rate: Defined as number of complications per group. Complications include surgical site infection, scrotal hematoma, bleeding, scrotal swelling, hernia formation, testicular atrophy, and wound dehiscence. Assessed 6-8 weeks post-surgery by a trained clinician who was not involved in administering surgery for this study. Success rate of procedure: Defined as number of testis successfully lowered into the lower scrotum at a 6-8 week follow-up visit evaluated by a trained clinician.

Being tested
Scrotal Orchidopexy, Inguinal Orchidopexy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Scrotal OrchidopexyProcedure or surgery

    Single incision

  • Inguinal OrchidopexyProcedure or surgery

    Double Incision (Standard)

Study groups in NCT02158780
Study groupRoleWhat they receive
Scrotal OrchidopexyExperimentalSingle incision
Receives: Procedure: Scrotal Orchidopexy
Inguinal OrchidopexyOtherDouble Incision (Standard)
Receives: Procedure: Inguinal Orchidopexy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Analgesic use post-operatively (during hospital stay)

    Defined as the number of doses of morphine (standardized dose of 0.2 mg/kg) or Tylenol (15mg/kg) or Ibuprofen (10mg/kg) administered by PACU and SDSU nurses following surgery.

    Measured: Measured dosage post-surgery (on average 45 minutes later)

  2. Analgesic use post-discharge

    Defined as number of standardized doses of Tylenol (15 mg/kg) and Ibuprofen (10 mg/kg) administered by parent/guardian at home post-discharge.

    Measured: Measure at 6 hour intervals post discharge for 48 hours

Secondary outcomes (9)
  1. Pain Scales post-operative (during hospital stay)

    Pain scores will be measured through a reliable and validated observer-rated Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) by two trained, blinded, and independent study personnel. Both study personnel will measure pain at admission and discharge during the recovery phase.

    Measured: Measure at patient admission and discharge at 30 minute intervals.

  2. Pain Scales post-operative (during hospital stay)

    Pain scores will be measured through a reliable and validated observer-rated Face, Legs, Activity, Cry, Consolability (FLACC) Behavioural Scale by two trained, blinded, and independent study personnel. Both study personnel will measure pain at admission and discharge during the recovery phase.

    Measured: Measure at patient admission and discharge at 30 minute intervals.

  3. Pain scales post-discharge

    Assessed through validated and reliable Parents Postoperative Pain Measure (PPPM) by trained and blinded parent/guardian at 6, 12,18, 24, 30, 36, 42, 48 hrs post-discharge

    Measured: Measure at 6 hour intervals post discharge for 48 hours

  4. Analgesic use

    Amount of pain medication administered to patient intra and post operatively

    Measured: Measured dosage at the beginning of surgery and post-surgery (on average 45minutes later)

  5. Duration of surgery (min)

    Obtained from operative case notes. Defined as beginning of first skin incision and ending when post-operative dressing has been applied.

    Measured: Record duration of operative time (takes on average 30-45 minutes)

  6. Time to discharge

    Defined as duration of time from entering PACU to discharge from day-surgery unit. Recording by study nurse on discharge sheet.

    Measured: Duration of time from being admitted for surgery until time discharged (which is on average 4 hours)

  7. Short term complications

    Examples include surgical site infection, scrotal hematoma, bleeding, scrotal swelling and wound dehiscence

    Measured: Measured at 48 hour follow-up clinic visit

  8. Long-term complications

    Examples include: hernia formation and testicular atrophy

    Measured: Measured at 3 and 6 month follow-up clinic visit

  9. Success rate

    Success rate in this study is defined by the number of viable testicles successfully positioned into the lower part of the scrotum.

    Measured: Measured at 3 month followup clinic visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2014 (estimated)
  2. Study startJan 2015
  3. Primary completion22 Feb 2021
  4. Study completion22 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
162 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02158780
Sponsor's protocol ID
EXPRESSO
Acronym
EXPRESSO
Status last verified
Aug 2019
First submitted
20 May 2014
Last updated
25 Feb 2021
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Scrotal Orchidopexy and Inguinal Orchidopexy in people with Low-lying Unilateral Palpable Undescended Testis, run by McMaster University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Analgesic use post-operatively (during hospital stay) (time frame: Measured dosage post-surgery (on average 45 minutes later)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in